We live in an impatient world where people expect instant gratification. I feel that one unfortunate aspect of Bluebird's openness has been that people expect updates every other week. I don't know of any drug trial where updates are made until a phase of the trial is completed, yet it's expected that we will get weekly updates on gene therapy, which will take longer to perfect than most drugs. I think the investment community has become just as affected by the need for instant gratification as anyone else. It will be really sad if this new normal results in new drugs and therapies being given up on and not funded because it's not happening fast enough to appease the immature investors. And the more I read the pharma biz press, the more I compare them to sportswriters, whose main goal is to tear down athletes. I see the same phenomenon taking place with these biz writers, who act like vultures waiting to swoop in and pronounce failure on therapies and drugs that are still in trials.